Search Results

Allogene Therapeutics, Inc. announced it will restate previously issued financial statements for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the December 2020 formation of the Allogene Overland Biopharm joint venture in Asia.

Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA.

Stereotaxis announced that physicians at Overland Park Regional Medical Center launched and successfully completed the first procedures using the advanced Genesis Robotic Magnetic Navigation System.

Overland Pharmaceuticals (“Overland”), a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, today announced the appointment of Xun Liu, Ph.D., as Chief Technology Officer (CTO).

Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced it has completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China.

Medline has expanded its broad consumer portfolio of mobility products with the inclusion of the new byACRE Overland Carbon Fiber Rollator, a lightweight assistive walking device durable and agile enough to operate in snow, sand and mud, as well as on sidewalks, curbs, unpaved trails and thick grass.

ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® announced its partnership with Overland Pharmaceuticals.

Overland Pharmaceuticals today announced the appointment of Co-founder Ed Zhang , MBA as full-time Chief Executive Officer after serving as Interim Chief Executive Officer since May 2021.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders.

Overland Pharmaceuticals, a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, announced the appointment of Roger Luo, Ph.D. as Chief Development Officer, Head of Clinical and Preclinical Development.